Novartis announced positive results from two pivotal Phase 3 clinical trials (Neptunus 1 and 2) demonstrating that its antibody drug ianalumab significantly reduced disease activity in patients with Sjögren’s syndrome. Targeting the BAFF-R protein, ianalumab achieved the primary endpoint of improved disease activity on the EULAR index at 52 weeks, with a favorable safety profile. This success marks a critical milestone as the first targeted treatment to show efficacy in this autoimmune condition. Novartis plans regulatory submissions aiming to address the unmet need in Sjögren’s disease therapeutics.